Security
Immunocore Holdings plc American Depositary Shares · IMCR
IMCRNASDAQotherCurrentCIK 1671927Updated Oct 8, 2026
Name history
Immunocore Ltd · through Feb 1, 2021
IMCR price & chart
Loading TradingView…
NASDAQ:IMCR on TradingView ↗About the company
Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX - Immune mobilizing monoclonal TCRs Against X disease - designed to treat a broad range of diseases, including cancer, autoimmune diseases and infectious diseases. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including clinical and pre-clinical programs in oncology, infectious diseases, and autoimmune diseases. The Company’s most advanced oncology TCR therapeutic, KIMMTRAK, has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.
In the news
No coverage from other publishers is available.
Recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 1,102,500,000Source | 1,084,638,000Source | 1,119,422,000Source | 1,082,387,000Source | 1,023,365,000Source | 1,072,095,000Source | 1,028,008,000Source | 993,987,000Source | 1,067,269,000Source | 1,009,506,000Source | 597,001,000Source | 435,518,000Source |
| Property, Plant and Equipment, NetUSD | 9,433,000Source | 9,160,000Source | 12,863,000Source | 9,548,000Source | 7,684,000Source | 12,128,000Source | 9,770,000Source | 8,380,000Source | 11,462,000Source | 10,092,000Source | 9,215,000Source | — |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 498,413,000Source | 537,767,000Source | 484,920,000Source | 487,933,000Source | 504,985,000Source | 452,675,000Source | 476,845,000Source | 832,821,000Source | 467,709,000Source | 455,731,000Source | 442,626,000Source | — |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | 63,659,000Source | — | — | 60,245,000Source | — | — | 57,754,000Source | — | 63,009,000Source | 52,093,000Source | — |
| Inventory, NetUSD | 5,655,000Source | 4,518,000Source | 7,791,000Source | 5,456,000Source | 3,462,000Source | 8,253,000Source | 6,804,000Source | 4,167,000Source | 6,742,000Source | 5,446,000Source | 4,501,000Source | — |
| Assets, CurrentUSD | 1,022,848,000Source | 1,005,905,000Source | 1,051,044,000Source | 1,002,298,000Source | 956,859,000Source | 1,003,807,000Source | 948,625,000Source | 926,038,000Source | 996,742,000Source | 929,864,000Source | 528,820,000Source | — |
| Prepaid Expense and Other Assets, CurrentUSD | 48,960,000Source | 36,446,000Source | 67,692,000Source | 44,270,000Source | 33,555,000Source | 69,590,000Source | 41,697,000Source | 31,296,000Source | 50,055,000Source | 41,033,000Source | 29,600,000Source | — |
| Operating Lease, Right-of-Use AssetUSD | 39,397,000Source | 39,672,000Source | 37,020,000Source | 39,428,000Source | 32,435,000Source | 37,546,000Source | 38,126,000Source | 32,812,000Source | 38,783,000Source | 37,643,000Source | 33,520,000Source | — |
| Other Assets, NoncurrentUSD | 16,489,000Source | 17,238,000Source | 18,495,000Source | 17,036,000Source | 16,276,000Source | 18,614,000Source | 17,132,000Source | 15,996,000Source | 20,282,000Source | 17,117,000Source | 14,473,000Source | — |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 705,936,000Source | 706,811,000Source | 699,624,000Source | 693,906,000Source | 664,228,000Source | 678,422,000Source | 649,529,000Source | 634,453,000Source | 686,236,000Source | 648,790,000Source | 228,158,000Source | 156,762,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 135,000Source | 135,000Source | 138,000Source | 135,000Source | 135,000Source | 137,000Source | 135,000Source | 135,000Source | 136,000Source | 135,000Source | 134,000Source | — |
| Additional Paid in CapitalUSD | 1,227,649,000Source | 1,180,854,000Source | 1,273,101,000Source | 1,215,997,000Source | 1,174,147,000Source | 1,247,212,000Source | 1,202,171,000Source | 1,163,872,000Source | 1,240,255,000Source | 1,190,104,000Source | 1,149,643,000Source | — |
| Retained Earnings (Accumulated Deficit)USD | -801,215,000Source | -771,990,000Source | -819,112,000Source | -801,038,000Source | -780,726,000Source | -818,304,000Source | -790,738,000Source | -769,110,000Source | -831,275,000Source | -795,761,000Source | -744,674,000Source | — |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -30,006,000Source | -31,173,000Source | -34,330,000Source | -26,614,000Source | -34,420,000Source | -35,373,000Source | -33,090,000Source | -35,364,000Source | -28,084,000Source | -33,763,000Source | -36,261,000Source | — |
| Stockholders' Equity Attributable to ParentUSD | 396,564,000Source | 377,827,000Source | 419,798,000Source | 388,481,000Source | 359,137,000Source | 393,673,000Source | 378,479,000Source | 359,534,000Source | 381,033,000Source | 360,716,000Source | 368,843,000Source | — |
| Liabilities and EquityUSD | 1,102,500,000Source | 1,084,638,000Source | 1,119,422,000Source | 1,082,387,000Source | 1,023,365,000Source | 1,072,095,000Source | 1,028,008,000Source | 993,987,000Source | 1,067,269,000Source | 1,009,506,000Source | 597,001,000Source | — |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 170,353,000Source | 266,249,000Source | 235,198,000Source | 170,078,000Source | 185,096,000Source | 240,113,000Source | 149,163,000Source | 155,293,000Source | 246,697,000Source | 212,181,000Source | 139,021,000Source | — |
| Operating Lease, Liability, CurrentUSD | 1,878,000Source | 1,097,000Source | 1,906,000Source | 1,843,000Source | 1,387,000Source | 1,996,000Source | 1,717,000Source | 1,243,000Source | 2,006,000Source | 1,547,000Source | 1,388,000Source | — |
| Accounts Payable, CurrentUSD | 22,956,000Source | 19,721,000Source | 26,319,000Source | 23,856,000Source | 19,947,000Source | 30,157,000Source | 29,105,000Source | 15,501,000Source | 24,364,000Source | 25,100,000Source | 17,798,000Source | — |
| Operating Lease, Liability, NoncurrentUSD | 41,397,000Source | 41,271,000Source | 38,847,000Source | 42,561,000Source | 33,445,000Source | 40,027,000Source | 40,748,000Source | 33,986,000Source | 41,556,000Source | 40,162,000Source | 34,633,000Source | — |
| Additional Financial Items | ||||||||||||
| CurrentTaxAssetsCurrentGBP | — | — | — | — | — | — | — | — | — | — | — | 11,688,000Source |
| Deferred Revenue, CurrentUSD | — | — | — | — | — | — | — | — | — | — | 0Source | — |
| Deferred Revenue, NoncurrentUSD | — | 5,797,000Source | — | — | 5,477,000Source | — | 5,612,000Source | 5,468,000Source | — | 5,434,000Source | 5,515,000Source | — |
| DeferredTaxAssetsGBP | — | — | — | — | — | — | — | — | — | — | — | 4,240,000Source |
| IssuedCapitalGBP | — | — | — | — | — | — | — | — | — | — | — | 97,000Source |
| TradeAndOtherCurrentPayablesGBP | — | — | — | — | — | — | — | — | — | — | — | 75,076,000Source |
| TradeAndOtherCurrentReceivablesGBP | — | — | — | — | — | — | — | — | — | — | — | 46,711,000Source |
| TradeAndOtherReceivablesGBP | — | — | — | — | — | — | — | — | — | — | — | 46,711,000Source |
| Long-term Debt | — | —Source | — | — | —Source | — | — | —Source | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Profit or LossGBP | — | — | — | — | — | — | — | — | — | — | — | -41,224,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | — | — | 3,100,000Source | 4,200,000Source | 4,100,000Source | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 6,302,000Source | 9,489,000Source | 37,698,000Source | 34,190,000Source | 32,469,000Source | — |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 7,930,000Source | -836,000Source | 7,336,000Source | 12,348,000Source | 17,871,000Source | — |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 5,974,000Source | 3,342,000Source | -2,456,000Source | 7,272,000Source | 2,625,000Source | — |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 14,790,000Source | -3,823,000Source | 5,843,000Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -13,775,000Source | 435,000Source | -10,712,000Source | 26,061,000Source | 2,940,000Source | — |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 4,219,000Source | 9,702,000Source | -16,340,000Source | -355,129,000Source | -5,425,000Source | — |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 1,781,000Source | 298,000Source | 4,340,000Source | 5,173,000Source | 5,425,000Source | — |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 656,000Source | 2,551,000Source | 12,371,000Source | 343,881,000Source | 34,346,000Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 498,413,000Source | 537,767,000Source | 484,920,000Source | 487,933,000Source | 452,675,000Source | 476,845,000Source | 467,709,000Source | 455,731,000Source | 442,626,000Source | — |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | 13,000Source | 32,000Source | 4,643,000Source | 510,000Source | -977,000Source | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | -6,134,000Source | 8,426,000Source | 26,659,000Source | -1,708,000Source | 8,293,000Source | — |
| Additional Financial Items | ||||||||||||
| AdjustmentsForCurrentTaxOfPriorPeriodGBP | — | — | — | — | — | — | — | — | — | — | — | 20,000Source |
| AdjustmentsForDecreaseIncreaseInTradeAccountReceivableGBP | — | — | — | — | — | — | — | — | — | — | — | -32,090,000Source |
| AdjustmentsForDeferredTaxOfPriorPeriodsGBP | — | — | — | — | — | — | — | — | — | — | — | -150,000Source |
| AdjustmentsForIncreaseDecreaseInTradeAccountPayableGBP | — | — | — | — | — | — | — | — | — | — | — | 38,747,000Source |
| AdjustmentsForSharebasedPaymentsGBP | — | — | — | — | — | — | — | — | — | — | — | 27,054,000Source |
| AdjustmentsForUnrealisedForeignExchangeLossesGainsGBP | — | — | — | — | — | — | — | — | — | — | — | -6,033,000Source |
| DepreciationUSD | — | — | — | — | — | — | 948,000Source | 854,000Source | 3,266,000Source | 4,204,000Source | 4,090,000Source | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | 1,333,000Source | 3,963,000Source | -1,108,000Source | -738,000Source | 3,849,000Source | 3,080,000Source | 2,215,000Source | -3,448,000Source | -13,176,000Source | — |
| Foreign Currency Transaction Gain (Loss), UnrealizedUSD | — | — | — | — | — | — | 3,490,000Source | 2,907,000Source | 6,385,000Source | -599,000Source | -13,827,000Source | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | 0Source | -3,853,000Source | 0Source | — |
| Income Tax Expense (Benefit)USD | — | — | 481,000Source | -2,643,000Source | 294,000Source | 606,000Source | 301,000Source | 1,061,000Source | 16,414,000Source | -1,850,000Source | -5,603,000Source | — |
| IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesGBP | — | — | — | — | — | — | — | — | — | — | — | -618,000Source |
| InterestExpenseNonoperatingUSD | — | — | 3,043,000Source | 4,290,000Source | 3,062,000Source | 3,045,000Source | 3,051,000Source | 3,025,000Source | 12,166,000Source | 18,844,000Source | — | — |
| Investment Income, InterestUSD | — | — | 4,123,000Source | 5,960,000Source | 3,582,000Source | 4,271,000Source | 3,418,000Source | 4,176,000Source | 16,476,000Source | 25,618,000Source | 17,986,000Source | — |
| Marketable Securities, Unrealized Gain (Loss)USD | — | — | — | — | — | — | 1,776,000Source | 5,469,000Source | 19,728,000Source | 14,577,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -177,000Source | 8,736,000Source | -808,000Source | -10,300,000Source | 12,971,000Source | 5,023,000Source | -35,514,000Source | -51,087,000Source | -55,287,000Source | — |
| OtherAdjustmentsToReconcileProfitLossGBP | — | — | — | — | — | — | — | — | — | — | — | 67,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 5,062,000Source | 8,962,000Source | 3,070,000Source | 4,693,000Source | 1,776,000Source | 5,469,000Source | 19,728,000Source | 14,198,000Source | -897,000Source | — |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesGBP | — | — | — | — | — | — | — | — | — | — | — | 3,208,000Source |
| Proceeds from Contributed CapitalUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | — |
| ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivitiesGBP | — | — | — | — | — | — | — | — | — | — | — | 5,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 656,000Source | 2,551,000Source | 12,371,000Source | 6,800,000Source | 34,346,000Source | — |
| PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesGBP | — | — | — | — | — | — | — | — | — | — | — | 410,000Source |
| RepaymentsOfBorrowingsClassifiedAsFinancingActivitiesGBP | — | — | — | — | — | — | — | — | — | — | — | 43,509,000Source |
| Interest Paid, Excluding Capitalized Interest, Operating Activities | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 103,693,000Source | 80,248,000Source | 115,927,000Source | 97,964,000Source | 106,677,000Source | 93,881,000Source | 400,016,000Source | 310,202,000Source | 238,735,000Source | 143,737,000Source |
| Cost of Goods and Services Sold | — | — | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source |
| Gross Profit (Calculated) · Derived | — | — | — | — | — | — | — | — | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | — | — | 39,779,000Source | 35,532,000Source | 43,890,000Source | 42,791,000Source | 37,850,000Source | 40,198,000Source | 165,413,000Source | 155,781,000Source | 144,495,000Source | 93,723,000Source |
| Operating Income (Loss)USD | — | — | -7,171,000Source | -8,502,000Source | -2,996,000Source | -14,875,000Source | 7,280,000Source | -3,616,000Source | -45,353,000Source | -70,461,000Source | -59,649,000Source | — |
| Other Nonoperating Income (Expense)USD | — | — | 5,062,000Source | 8,962,000Source | 3,070,000Source | 4,693,000Source | 1,776,000Source | 5,469,000Source | 19,728,000Source | 14,198,000Source | -897,000Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | 304,000Source | 6,093,000Source | -514,000Source | -9,694,000Source | 13,272,000Source | 6,084,000Source | -19,100,000Source | -52,937,000Source | -60,890,000Source | — |
| Income Tax Expense (Benefit)USD | — | — | 481,000Source | -2,643,000Source | 294,000Source | 606,000Source | 301,000Source | 1,061,000Source | 16,414,000Source | -1,850,000Source | -5,603,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -177,000Source | 8,736,000Source | -808,000Source | -10,300,000Source | 12,971,000Source | 5,023,000Source | -35,514,000Source | -51,087,000Source | -55,287,000Source | — |
| Earnings Per Share, BasicUSD per share | — | — | 0Source | 0.17Source | -0.02Source | -0.2Source | 0.26Source | 0.1Source | -0.71Source | -1.02Source | -1.13Source | — |
| Earnings Per Share, DilutedUSD per share | — | — | 0Source | 0.17Source | -0.02Source | -0.2Source | 0.25Source | 0.1Source | -0.71Source | -1.02Source | -1.13Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 50,403,717Source | 50,021,939Source | 50,973,830Source | 50,294,205Source | 50,754,763Source | 50,086,684Source | 50,345,666Source | 49,991,064Source | 48,888,975Source | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 50,403,717Source | 52,808,434Source | 50,973,830Source | 50,294,205Source | 52,934,787Source | 51,949,798Source | 50,345,666Source | 49,991,064Source | 48,888,975Source | — |
| Interest Expense (non-operating)USD | — | — | 3,043,000Source | 4,290,000Source | 3,062,000Source | 3,045,000Source | 3,051,000Source | 3,025,000Source | 12,166,000Source | 18,844,000Source | — | — |
| Additional Financial Items | ||||||||||||
| BasicEarningsLossPerShareGBP/shares | — | — | — | — | — | — | — | — | — | — | — | -0.9Source |
| Common Stock, Dividends, Per Share, DeclaredUSD per share | — | — | — | — | — | — | — | — | 0Source | 0Source | — | — |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 1,624,000Source | 1,973,000Source | -240,000Source | — |
| CurrentTaxExpenseIncomeGBP | — | — | — | — | — | — | — | — | — | — | — | -1,406,000Source |
| DeferredTaxExpenseIncomeGBP | — | — | — | — | — | — | — | — | — | — | — | -1,515,000Source |
| DeferredTaxExpenseIncomeRecognisedInProfitOrLossGBP | — | — | — | — | — | — | — | — | — | — | — | -1,352,000Source |
| DepreciationRightofuseAssetsGBP | — | — | — | — | — | — | — | — | — | — | — | 1,827,000Source |
| DilutedEarningsLossPerShareGBP/shares | — | — | — | — | — | — | — | — | — | — | — | -0.9Source |
| EmployeeBenefitsExpenseGBP | — | — | — | — | — | — | — | — | — | — | — | 68,813,000Source |
| FinanceCostsGBP | — | — | — | — | — | — | — | — | — | — | — | 7,692,000Source |
| FinanceIncomeGBP | — | — | — | — | — | — | — | — | — | — | — | 3,154,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | 1,333,000Source | 3,963,000Source | -1,108,000Source | -738,000Source | 3,849,000Source | 3,080,000Source | 2,215,000Source | -3,448,000Source | -13,176,000Source | — |
| IncomeTaxExpenseContinuingOperationsGBP | — | — | — | — | — | — | — | — | — | — | — | -2,921,000Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 5,154,000Source | — |
| Interest Expense, DebtUSD | — | — | 3,043,000Source | 4,290,000Source | 3,062,000Source | 3,045,000Source | 3,051,000Source | 3,025,000Source | 12,166,000Source | 18,844,000Source | — | — |
| InterestExpenseOnLeaseLiabilitiesGBP | — | — | — | — | — | — | — | — | — | — | — | 1,796,000Source |
| Investment Income, InterestUSD | — | — | 4,123,000Source | 5,960,000Source | 3,582,000Source | 4,271,000Source | 3,418,000Source | 4,176,000Source | 16,476,000Source | 25,618,000Source | 17,986,000Source | — |
| OperatingLeaseIncomeGBP | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| OtherOperatingIncomeExpenseGBP | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| PostemploymentBenefitExpenseDefinedContributionPlansGBP | — | — | — | — | — | — | — | — | — | — | — | 1,355,000Source |
| ProfitLossBeforeTaxGBP | — | — | — | — | — | — | — | — | — | — | — | -44,145,000Source |
| ProfitLossFromOperatingActivitiesGBP | — | — | — | — | — | — | — | — | — | — | — | -39,607,000Source |
| Research and Development ExpenseUSD | — | — | 70,572,000Source | 52,770,000Source | 73,945,000Source | 69,008,000Source | 61,113,000Source | 56,468,000Source | 274,869,000Source | 222,151,000Source | 163,545,000Source | 89,170,000Source |
| RevenueGBP | — | — | — | — | — | — | — | — | — | — | — | 143,737,000Source |
Filing attachments
ef20072226_ex107.htm · S-8 · 2026-05-08
Exhibit 107 CALCULATION OF FILING FEE TABLE S-8 (Form Type) Immunocore Holdings plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Maximum Aggregate Fee Rate Amount of Registration Fee …
Read attachment ↗ef20072537_ex99-1.htm · 8-K · 2026-05-06
EX-99.1 2 ef20072537_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) Q1 net sales of $106.7 million, growing by 14% year-over-year Oral presentation at AACR: KIMMTRAK doubles likelihood of being alive at five years for patients with HLA-A*02:01 positive metastatic uveal melanoma Cash, cash equivalents and marketable securities of $845 million as of March 31, 2026 (OXFORDSHIRE, England & R…
Read attachment ↗ef20066378_ex99-1.htm · 8-K · 2026-02-25
EX-99.1 2 ef20066378_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Immunocore reports fourth quarter and full year 2025 financial results and provides a business update KIMMTRAK (tebentafusp-tebn) Q4 net sales of $104.5 million and $400.0 million for full year 2025; expect moderating revenue growth in 2026 TEBE-AM enrollment completion anticipated 1H 2026 with topline data expected as early as 2H 2026 PRAME franchise Phase 1/2 data to be presented in 2H 2026: brenetafusp in ovarian and lung cance…
Read attachment ↗ef20062561_ex99-1.htm · 8-K · 2026-01-09
Exhibit 99.1 Immunocore announces 2026 strategic priorities at 44 Reaching more metastatic uveal melanoma patients with KIMMTRAK (tebentafusp) in 2026 through US community and global market penetration Enrolling three Phase 3 trials across multiple melanoma indications - TEBE-AM enrollment completion anticipated 1H 2026; topline data expected as early as 2H 2026 PRAME franchise Phase 1/2 data to be presented in 2H 2026: brenetafusp combinations in ovarian and lung cancer and initial data wit…
Read attachment ↗ef20062561_ex99-2.htm · 8-K · 2026-01-09
Exhibit 99.2 Transformative immunomodulating medicines for patients January 2026 1 2 Forward Looking Statements This presentation contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “may”, “will”, “believe”, “expect”, “plan”, “anticipate”, “estimate”, “expect”, “continue” and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended…
Read attachment ↗ef20058378_ex99-1.htm · 8-K · 2025-11-06
EX-99.1 2 ef20058378_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Immunocore reports third quarter financial results and provides a business update KIMMTRAK Phase 3 TEBE-AM trial on track to complete enrollment in 1H 2026 160 mcg selected as the go-forward dose for brenetafusp in Phase 3 PRISM-MEL-301 trial, following Independent Data Monitoring Committee review Cash, cash equivalents and marketable securities of $892 million as of September 30, 2025 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn.…
Read attachment ↗